ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

All Content

The FDA approved olaparib as maintenance therapy for adult patients with recurrent ovarian cancer. The agent is also now approved in tablet form.

The US Senate passed legislation that would support and help accelerate the development of promising drugs for children with cancer.

What is the real-world economic burden associated with complications from hematopoietic cell transplantation? What prognostic factors for posttransplantation outcomes among patients with chronic myelomonocytic leukemia are significant predictors of survival? Answer these and more in our latest quiz.

Prolonged use of bortezomib after treatment with combined bortezomib plus dexamethasone did not result in any significant benefit for patients with relapsed/refractory multiple myeloma compared with bortezomib plus dexamethasone alone, but this less dose-intensive approach could be a feasible option for patients who cannot tolerate the standard regimen.

The rate of lymph node positivity in patients with squamous cell carcinoma of the anus may be overestimated, potentially leading to the overtreatment of patients with chemoradiotherapy.

Significant racial and gender-based disparities exist in outcomes among patients with squamous cell carcinoma of the anus, with black men having the lowest survival rates, according to a new study.

In this interview we discuss a recent study that linked periodontal disease with an increased cancer risk, specifically melanoma and cancers of the lung, breast, esophagus, and gallbladder.

The FDA has approved inotuzumab ozogamicin (Besponsa) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Dual action: microtubule inhibition and vascular remodeling in human breast cancer models.

Ricardo Alvarez, MD

A 21-year-old woman develops a nodule in her left breast, and a biopsy is obtained. What your diagnosis?

Pages

By clicking Accept, you agree to become a member of the UBM Medica Community.